⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for chronic myelomonocytic leukemia

Every month we try and update this database with for chronic myelomonocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Bryostatin 1 in Treating Patients With Myelodysplastic SyndromeNCT00003171
Leukemia
Myelodysplastic...
bryostatin 1
18 Years - Barbara Ann Karmanos Cancer Institute
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationNCT00052520
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
B-cell Adult Ac...
B-cell Childhoo...
Childhood Chron...
Childhood Myelo...
Chronic Myelomo...
Essential Throm...
Polycythemia Ve...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Refractory Anem...
Refractory Anem...
Relapsing Chron...
Secondary Acute...
T-cell Adult Ac...
T-cell Childhoo...
therapeutic all...
aldesleukin
peripheral bloo...
allogeneic bone...
laboratory biom...
gene expression...
immunologic tec...
flow cytometry
polymerase chai...
cytogenetic ana...
staining method
- Fred Hutchinson Cancer Center
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesNCT01823198
Accelerated Pha...
Acute Erythroid...
Acute Megakaryo...
Acute Myeloid L...
Acute Myeloid L...
Acute Myeloid L...
Blast Phase Chr...
Blasts Under 20...
Blasts Under 20...
Chronic Myelomo...
High Risk Myelo...
Myelodysplastic...
Recurrent Chron...
Therapy-Related...
Therapy-Related...
Aldesleukin
Allogeneic CD56...
Allogeneic Hema...
Busulfan
Fludarabine Pho...
Laboratory Biom...
Peripheral Bloo...
Pharmacological...
7 Years - 65 YearsM.D. Anderson Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDSNCT01300572
Chronic Myelomo...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Secondary Acute...
Allogeneic Bone...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Indium In 111 A...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Pharmacological...
Total-Body Irra...
Yttrium Y 90 An...
18 Years - Fred Hutchinson Cancer Center
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesNCT03263637
Relapsed or Ref...
Acute Myeloid L...
Acute Lymphocyt...
Chronic Lymphoc...
High Risk Myelo...
Chronic Myelomo...
Richter's Syndr...
B-cell Non-Hodg...
T-cell Non-Hodg...
Small Lymphocyt...
Multiple Myelom...
AZD4573
18 Years - 130 YearsAstraZeneca
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and AnemiaNCT00843882
Anemia
Chronic Myelomo...
de Novo Myelody...
Myelodysplastic...
Bone Marrow Bio...
Epoetin Alfa
Laboratory Biom...
Lenalidomide
18 Years - National Cancer Institute (NCI)
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic CancersNCT00015951
Leukemia
Myelodysplastic...
bevacizumab
cytarabine
mitoxantrone hy...
18 Years - 120 YearsUniversity of Maryland, Baltimore
Inqovi Maintenance Therapy in Myeloid NeoplasmsNCT04980404
Myelodysplastic...
Chronic Myelomo...
Stem Cell Leuke...
Inqovi
18 Years - Massachusetts General Hospital
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic LeukemiaNCT00003619
Chronic Myelopr...
Leukemia
Myelodysplastic...
Thrombocytopeni...
filgrastim
vitamin E
busulfan
cytarabine
etoposide
fludarabine pho...
isotretinoin
topotecan hydro...
bone marrow abl...
peripheral bloo...
19 Years - 90 YearsNational Cancer Institute (NCI)
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaNCT00451048
Chronic Myelomo...
de Novo Myelody...
Myelodysplastic...
Secondary Myelo...
sunitinib malat...
18 Years - National Cancer Institute (NCI)
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsNCT04493138
Chronic Myelomo...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Myelo...
Recurrent Myelo...
Azacitidine
Quizartinib
18 Years - M.D. Anderson Cancer Center
Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)NCT00074750
Acute Myelogeno...
Chronic Myelomo...
DTGM
18 Years - M.D. Anderson Cancer Center
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic SyndromesNCT00398047
Leukemia
Myelodysplastic...
Azacitadine and...
- 120 YearsWake Forest University Health Sciences
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaNCT06085638
Chronic Myelomo...
Azacitidine
Tamibarotene
Venetoclax
18 Years - M.D. Anderson Cancer Center
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)NCT01048034
Myelodysplastic...
Chronic Myelomo...
Azacitidine
Erythropoetin
18 Years - Nordic MDS Group
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationNCT03602898
Acute Lymphobla...
Acute Myeloid L...
Chronic Myelomo...
Chronic Phase C...
Hematopoietic a...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Recurrent Acute...
Recurrent Hodgk...
Recurrent Non-H...
Refractory Acut...
Therapy-Related...
Anti-Thymocyte ...
Busulfan
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Methotrexate
Peripheral Bloo...
Quality-of-Life...
Questionnaire A...
Tacrolimus
Total-Body Irra...
- 65 YearsFred Hutchinson Cancer Center
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseNCT04146038
Acute Myeloid L...
Chronic Myelomo...
Myeloblasts 10 ...
Myelodysplastic...
Myeloproliferat...
Recurrent Acute...
Refractory Acut...
Secondary Acute...
Azacitidine
Decitabine
Salsalate
Venetoclax
18 Years - Rutgers, The State University of New Jersey
Haplo Peripheral Blood Sct In GVHD PreventionNCT04473911
GVHD
AML
ALL
MDS
MPN
CMML
Hodgkin Lymphom...
Non Hodgkin Lym...
Blood Stem Cell...
Graft Vs Host D...
Acute Myeloid L...
Acute Lymphobla...
Myelodysplastic...
Myeloproliferat...
Chronic Myelomo...
Chemosensitive ...
FLUDARABINE
CYCLOPHOSPHAMID...
TBI
Melphalan
Sirolimus
Mycophenolate m...
RGI-2001
CYCLOPHOSPHAMID...
18 Years - 80 YearsMassachusetts General Hospital
VNP40101M and Cytarabine in Treating Patients With Hematologic MalignanciesNCT00070538
Leukemia
Myelodysplastic...
cytarabine
laromustine
18 Years - National Cancer Institute (NCI)
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesNCT00234000
Leukemia
Myelodysplastic...
arsenic trioxid...
azacitidine
18 Years - Jonsson Comprehensive Cancer Center
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic SyndromeNCT00003415
Leukemia
Myelodysplastic...
amifostine trih...
topotecan hydro...
18 Years - National Cancer Institute (NCI)
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic SyndromeNCT02553941
Chronic Myelomo...
de Novo Myelody...
Previously Trea...
Refractory Anem...
Secondary Myelo...
Azacitidine
Ibrutinib
18 Years - University of California, Davis
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic SyndromeNCT00002800
Leukemia
Myelodysplastic...
Neutropenia
filgrastim
lintuzumab
cytarabine
etoposide
idarubicin
18 Years - Memorial Sloan Kettering Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDSNCT01300572
Chronic Myelomo...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Secondary Acute...
Allogeneic Bone...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Indium In 111 A...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Pharmacological...
Total-Body Irra...
Yttrium Y 90 An...
18 Years - Fred Hutchinson Cancer Center
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic SyndromesNCT03363399
Myelodysplastic...
Chronic Myelomo...
Flow cytometry ...
50 Years - University Hospital, Grenoble
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerNCT00003661
Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 YearsRoswell Park Cancer Institute
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell TransplantNCT05031897
Acute Lymphobla...
Acute Myeloid L...
Aplastic Anemia
Chronic Lymphoc...
Chronic Myelomo...
Essential Throm...
Hematopoietic a...
Hodgkin Lymphom...
Myelodysplastic...
Myelofibrosis
Myeloid Leukemi...
Myeloid Neoplas...
Non-Hodgkin Lym...
Plasma Cell Mye...
Polycythemia Ve...
Small Lymphocyt...
Hematopoietic C...
Mycophenolate M...
Tacrolimus
Cyclophosphamid...
Total-Body Irra...
Donor Lymphocyt...
Fludarabine
Melphalan
18 Years - Thomas Jefferson University
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersNCT00588991
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Chronic Myeloid...
Chronic Myelomo...
de Novo Myelody...
Essential Throm...
Hematopoietic a...
Myelodysplastic...
Polycythemia Ve...
Recurrent Adult...
Recurrent Adult...
Secondary Myelo...
Carboplatin
Laboratory Biom...
Topotecan Hydro...
Veliparib
18 Years - National Cancer Institute (NCI)
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerNCT00027820
Adult Acute Mye...
Childhood Acute...
Childhood Acute...
Childhood Myelo...
Childhood Renal...
Chronic Myelomo...
Clear Cell Rena...
de Novo Myelody...
Metastatic Rena...
Previously Trea...
Progression of ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Refractory Anem...
Refractory Anem...
Refractory Chil...
Refractory Chro...
Renal Medullary...
Type 1 Papillar...
Type 2 Papillar...
Untreated Adult...
Untreated Adult...
Untreated Child...
Fludarabine Pho...
Total-Body Irra...
Peripheral Bloo...
Nonmyeloablativ...
Cyclosporine
Mycophenolate M...
- Fred Hutchinson Cancer Center
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionNCT06218628
Primary Myelofi...
Post-polycythem...
Post-essential ...
Chronic Myelomo...
Polycythemia Ve...
Essential Throm...
Talazoparib
pacritinib
18 Years - Fox Chase Cancer Center
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)NCT04266301
Myelodysplastic...
Leukemia, Myelo...
Sabatolimab
Azacitidine
Placebo
18 Years - Novartis
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromeNCT03047993
Acute Myeloid L...
Blasts 20-30 Pe...
Blasts 20-30 Pe...
Chronic Myelomo...
High Risk Myelo...
IPSS Risk Categ...
Myelodysplastic...
Azacitidine
Glutaminase Inh...
18 Years - M.D. Anderson Cancer Center
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesNCT02566304
Acute Myeloid L...
Acute Myeloid L...
Aplastic Anemia
Chronic Myelomo...
Hodgkin Lymphom...
Indolent Non-Ho...
Malignant Neopl...
Myelodysplastic...
Myeloproliferat...
Plasma Cell Mye...
Refractory Anem...
Refractory Anem...
Refractory Anem...
Refractory Cyto...
Refractory Cyto...
Fludarabine
Total-Body Irra...
T Cell-Depleted...
Cyclophosphamid...
Peripheral Bloo...
Allogeneic Hema...
Tacrolimus
Mycophenolate m...
Laboratory Biom...
18 Years - Thomas Jefferson University
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaNCT00392353
Acute Erythroid...
Acute Megakaryo...
Acute Myeloid L...
Chronic Myelomo...
Myelodysplastic...
Myelodysplastic...
Myelodysplastic...
Recurrent Adult...
Refractory Anem...
Azacitidine
Laboratory Biom...
Pharmacological...
Vorinostat
18 Years - National Cancer Institute (NCI)
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromesNCT00352001
Leukemia
Myelodysplastic...
azacitidine
lenalidomide
18 Years - 120 YearsCase Comprehensive Cancer Center
Chemotherapy in Treating Patients Who Have Hematologic CancerNCT00004047
Leukemia
Myelodysplastic...
exatecan mesyla...
- Daiichi Sankyo
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCYNCT00809276
Lymphoma
Multiple Myelom...
Leukemia
Myelodysplastic...
Busulfan, Fluda...
- 65 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateNCT00038675
Chronic Myelomo...
Chronic Myeloid...
Polycythemia Ve...
Hypereosinophil...
Mastocytosis
Imatinib Mesyla...
- M.D. Anderson Cancer Center
Paricalcitol in Treating Patients With Myelodysplastic SyndromeNCT00064376
Leukemia
Myelodysplastic...
paricalcitol
25 Years - 100 YearsCedars-Sinai Medical Center
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)NCT01404741
Myelodysplastic...
Chronic Myelomo...
allogeneic stem...
5-azacytidine u...
55 Years - 70 YearsUniversitätsklinikum Hamburg-Eppendorf
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow TransplantationNCT00005641
Chronic Myelopr...
Graft Versus Ho...
Leukemia
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
busulfan
cyclophosphamid...
cyclosporine
leucovorin calc...
methotrexate
methylprednisol...
allogeneic bone...
in vitro-treate...
radiation thera...
15 Years - 60 YearsH. Lee Moffitt Cancer Center and Research Institute
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486NCT03493646
Myelodysplastic...
Acute Myeloid L...
Chronic Myelomo...
Azacitidine
CC-486
18 Years - Kirby Institute
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaNCT00087204
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Chronic Myelomo...
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Refractory Anem...
Relapsing Chron...
Secondary Acute...
Secondary Myelo...
becatecarin
laboratory biom...
18 Years - National Cancer Institute (NCI)
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic SyndromesNCT00997243
Leukemia
Myelodysplastic...
lintuzumab
5-azacytidine
18 Years - Ohio State University Comprehensive Cancer Center
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic SyndromeNCT03670966
Acute Lymphobla...
Acute Myeloid L...
Acute Myeloid L...
Chronic Myelomo...
Myelodysplastic...
Recurrent Acute...
Recurrent Acute...
Refractory Acut...
Refractory Acut...
Recurrent Mixed...
Refractory Mixe...
Hematopoietic a...
Astatine At 211...
Cyclophosphamid...
Total-Body Irra...
Peripheral Bloo...
Bone Marrow Tra...
Mycophenolate M...
Recombinant Gra...
Fludarabine Pho...
Tacrolimus
Bone Marrow Asp...
Biospecimen Col...
18 Years - 75 YearsFred Hutchinson Cancer Center
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedNCT02935361
Chronic Myelomo...
Myelodysplastic...
Recurrent Acute...
Atezolizumab
Guadecitabine
18 Years - University of Southern California
Oral Clofarabine Study in Patients With Myelodysplastic SyndromeNCT00299156
Myelodysplastic...
Chronic Myelomo...
Clofarabine
- M.D. Anderson Cancer Center
VNP40101M and Cytarabine in Treating Patients With Hematologic MalignanciesNCT00070538
Leukemia
Myelodysplastic...
cytarabine
laromustine
18 Years - National Cancer Institute (NCI)
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaNCT00118196
Leukemia
Myelodysplastic...
arsenic trioxid...
azacitidine
18 Years - 120 YearsMedical University of South Carolina
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)NCT04155580
Acute Myeloid L...
ASTX660
ASTX727
18 Years - Astex Pharmaceuticals, Inc.
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT00119366
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Childhood Myelo...
Chronic Myelomo...
Previously Trea...
Recurrent Adult...
Recurrent Child...
Refractory Anem...
Refractory Anem...
Refractory Anem...
Refractory Cyto...
Secondary Acute...
Secondary Myelo...
iodine I 131 mo...
fludarabine pho...
total-body irra...
allogeneic hema...
peripheral bloo...
cyclosporine
mycophenolate m...
laboratory biom...
16 Years - 50 YearsFred Hutchinson Cancer Center
Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)NCT00074750
Acute Myelogeno...
Chronic Myelomo...
DTGM
18 Years - M.D. Anderson Cancer Center
Registry on Hypomethylating Agents in Myeloid NeoplasmsNCT01595295
Chronic Myelomo...
Myelodysplastic...
Acute Myeloid L...
non interventio...
18 Years - Arbeitsgemeinschaft medikamentoese Tumortherapie
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)NCT04266301
Myelodysplastic...
Leukemia, Myelo...
Sabatolimab
Azacitidine
Placebo
18 Years - Novartis
Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDSNCT00744536
Myelodysplastic...
Leukemia, Myelo...
Angiogenesis
Lenalidomide an...
18 Years - Sunnybrook Health Sciences Centre
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid LeukemiaNCT00005866
Leukemia
Myelodysplastic...
busulfan
cyclophosphamid...
cyclosporine
methotrexate
allogeneic bone...
radiation thera...
16 Years - 55 YearsSWOG Cancer Research Network
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)NCT01404741
Myelodysplastic...
Chronic Myelomo...
allogeneic stem...
5-azacytidine u...
55 Years - 70 YearsUniversitätsklinikum Hamburg-Eppendorf
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerNCT00296023
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
filgrastim
therapeutic all...
busulfan
fludarabine pho...
methotrexate
tacrolimus
nonmyeloablativ...
peripheral bloo...
18 Years - 75 YearsUniversity of California, San Francisco
Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic MalignanciesNCT00356928
Leukemia
Myelodysplastic...
Cyclophosphamid...
Donor T cells
18 Years - 120 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSNCT04708054
Acute Myeloid L...
Chronic Myelomo...
Myelodysplastic...
Busulfan
Cladribine
Fludarabine Pho...
Hematopoietic C...
Thiotepa
Venetoclax
18 Years - 70 YearsM.D. Anderson Cancer Center
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous LeukemiaNCT00002926
Leukemia
Myelodysplastic...
cytarabine
etoposide
idarubicin
allogeneic bone...
peripheral bloo...
16 Years - 60 YearsNational Cancer Institute (NCI)
Inqovi Maintenance Therapy in Myeloid NeoplasmsNCT04980404
Myelodysplastic...
Chronic Myelomo...
Stem Cell Leuke...
Inqovi
18 Years - Massachusetts General Hospital
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486NCT03493646
Myelodysplastic...
Acute Myeloid L...
Chronic Myelomo...
Azacitidine
CC-486
18 Years - Kirby Institute
Vaccine Therapy in Treating Patients With Myelodysplastic SyndromeNCT00003959
Leukemia
Myelodysplastic...
ras peptide can...
sargramostim
17 Years - Memorial Sloan Kettering Cancer Center
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic LeukemiaNCT05209152
Higher Risk Mye...
Chronic Myelomo...
AMG 176
Azacitidine
18 Years - 85 YearsAmgen
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic SyndromeNCT01254890
Leukemia
Azacitidine
Sorafenib
18 Years - M.D. Anderson Cancer Center
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic CancerNCT00782379
Leukemia
Lymphoma
Myelodysplastic...
busulfan
cyclophosphamid...
fludarabine pho...
mycophenolate m...
tacrolimus
allogeneic hema...
peripheral bloo...
18 Years - 60 YearsNorthside Hospital, Inc.
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerNCT00003661
Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 YearsRoswell Park Cancer Institute
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDSNCT05456269
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Higher Risk Mye...
Chronic Myelomo...
Bisantrene Dihy...
Bisantrene Dihy...
Cytarabine Hydr...
Decitabine and ...
18 Years - Race Oncology Ltd
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSNCT04358393
AML
Acute Myeloid L...
Chronic Myelomo...
CMML
Myelodysplastic...
High-risk Myelo...
MDS
APG-115
5-azacitidine
18 Years - Ascentage Pharma Group Inc.
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisNCT06001385
Acute Lymphobla...
Acute Myeloid L...
Acute Leukemia
Myelodysplastic...
Chronic Myeloid...
Chronic Lymphoc...
Myeloproliferat...
Lymphoma
Chronic Myelomo...
Pro-Lymphocytic...
Myelofibrosis
Busulfan
Fludarabine
PBSC Hematopoie...
Post-Transplant...
Mesna
Tacrolimus
Mycophenolate M...
Patient Reporte...
Melphalan
Total-body irra...
Cyclophosphamid...
18 Years - Center for International Blood and Marrow Transplant Research
Haplo Peripheral Blood Sct In GVHD PreventionNCT04473911
GVHD
AML
ALL
MDS
MPN
CMML
Hodgkin Lymphom...
Non Hodgkin Lym...
Blood Stem Cell...
Graft Vs Host D...
Acute Myeloid L...
Acute Lymphobla...
Myelodysplastic...
Myeloproliferat...
Chronic Myelomo...
Chemosensitive ...
FLUDARABINE
CYCLOPHOSPHAMID...
TBI
Melphalan
Sirolimus
Mycophenolate m...
RGI-2001
CYCLOPHOSPHAMID...
18 Years - 80 YearsMassachusetts General Hospital
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesNCT00171912
Hypereosinophil...
Systemic Mastoc...
Chronic Myelomo...
Dermatofibrosar...
imatinib mesyla...
16 Years - 80 YearsNovartis
FTS Study in Patients With Advanced Hematologic MalignanciesNCT00867230
Myelodysplastic...
Leukemia
FTS
18 Years - M.D. Anderson Cancer Center
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic SyndromeNCT00002547
Leukemia
Myelodysplastic...
busulfan
cyclophosphamid...
cyclosporine
cytarabine
methotrexate
allogeneic bone...
syngeneic bone ...
- 60 YearsBarbara Ann Karmanos Cancer Institute
Imatinib Mesylate in Treating Patients With MyelofibrosisNCT00039416
Chronic Myelomo...
Essential Throm...
Polycythemia Ve...
Primary Myelofi...
imatinib mesyla...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic SyndromeNCT00002798
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Myelo...
Chronic Myelomo...
de Novo Myelody...
Refractory Anem...
Refractory Anem...
Refractory Anem...
Refractory Anem...
Secondary Myelo...
Untreated Child...
asparaginase
daunorubicin hy...
fludarabine pho...
therapeutic hyd...
allogeneic bone...
3-dimensional c...
filgrastim
cytarabine
idarubicin
dexamethasone
thioguanine
etoposide
methotrexate
cyclophosphamid...
aldesleukin
busulfan
- 21 YearsNational Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDSNCT01300572
Chronic Myelomo...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Secondary Acute...
Allogeneic Bone...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Indium In 111 A...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Pharmacological...
Total-Body Irra...
Yttrium Y 90 An...
18 Years - Fred Hutchinson Cancer Center
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateNCT00038675
Chronic Myelomo...
Chronic Myeloid...
Polycythemia Ve...
Hypereosinophil...
Mastocytosis
Imatinib Mesyla...
- M.D. Anderson Cancer Center
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological MalignanciesNCT02193958
AML
CMML
MDS
FF-10501-01
18 Years - Fujifilm Pharmaceuticals U.S.A., Inc.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: